Molero-Abraham Magdalena, Lafuente Esther M, Flower Darren R, Reche Pedro A
Facultad de Medicina, Sección de Inmunología, Universidad Complutense de Madrid, Avenida Complutense S/N, 28040 Madrid, Spain.
School of Life and Health Sciences, University of Aston, Aston Triangle, Birmingham B4 7ET, UK.
Clin Dev Immunol. 2013;2013:601943. doi: 10.1155/2013/601943. Epub 2013 Nov 21.
The hepatitis C virus (HCV) is able to persist as a chronic infection, which can lead to cirrhosis and liver cancer. There is evidence that clearance of HCV is linked to strong responses by CD8 cytotoxic T lymphocytes (CTLs), suggesting that eliciting CTL responses against HCV through an epitope-based vaccine could prove an effective means of immunization. However, HCV genomic plasticity as well as the polymorphisms of HLA I molecules restricting CD8 T-cell responses challenges the selection of epitopes for a widely protective vaccine. Here, we devised an approach to overcome these limitations. From available databases, we first collected a set of 245 HCV-specific CD8 T-cell epitopes, all known to be targeted in the course of a natural infection in humans. After a sequence variability analysis, we next identified 17 highly invariant epitopes. Subsequently, we predicted the epitope HLA I binding profiles that determine their potential presentation and recognition. Finally, using the relevant HLA I-genetic frequencies, we identified various epitope subsets encompassing 6 conserved HCV-specific CTL epitopes each predicted to elicit an effective T-cell response in any individual regardless of their HLA I background. We implemented this epitope selection approach for free public use at the EPISOPT web server.
丙型肝炎病毒(HCV)能够以慢性感染的形式持续存在,这可能导致肝硬化和肝癌。有证据表明,HCV的清除与CD8细胞毒性T淋巴细胞(CTL)的强烈反应有关,这表明通过基于表位的疫苗引发针对HCV的CTL反应可能是一种有效的免疫方法。然而,HCV基因组的可塑性以及限制CD8 T细胞反应的HLA I分子的多态性对广泛保护性疫苗表位的选择提出了挑战。在此,我们设计了一种方法来克服这些限制。我们首先从可用数据库中收集了一组245个HCV特异性CD8 T细胞表位,所有这些表位在人类自然感染过程中均已知会成为靶点。经过序列变异性分析后,我们接下来鉴定出17个高度保守的表位。随后,我们预测了决定其潜在呈递和识别的表位HLA I结合谱。最后,利用相关的HLA I基因频率,我们鉴定出了各种表位子集,每个子集包含6个保守的HCV特异性CTL表位,预计无论个体的HLA I背景如何,这些表位都能在任何个体中引发有效的T细胞反应。我们在EPISOPT网络服务器上免费供公众使用这种表位选择方法。